Complete Filing Data
Apimeds Pharmaceuticals US, Inc. reported Stockholders Equity of -$713.6 thousand for FY2022.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Apimeds Pharmaceuticals US, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 |
|---|---|---|
| Net Income Loss | -$1.4M | -$777.7K |
| Operating Income Loss | -$1.3M | -$747.4K |
| Nonoperating Income Expense | -$114.9K | -$30.3K |
| Interest Expense Nonoperating | $117.7K | $38.1K |
| General And Administrative Expense | $1.3M | $648.9K |
| Accrued Interest Expense Related Parties | $37.8K | $33.0K |
| Research And Development Expense | $98.5K | |
| Operating Expenses |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income Loss | -$1.8M | -$2.7M | -$402.4K | -$332.5K | -$449.4K | -$296.5K |
| Operating Income Loss | -$1.8M | -$2.7M | -$364.4K | -$300.0K | -$427.8K | -$271.7K |
| Nonoperating Income Expense | $63.0K | $1.7K | -$38.0K | -$32.5K | -$21.6K | -$24.7K |
| Interest Expense Nonoperating | $6.3K | $23.1K | $38.0K | $32.6K | $22.1K | $26.9K |
| General And Administrative Expense | $1.2M | $2.0M | $364.4K | $300.0K | $427.8K | $271.7K |
| Accrued Interest Expense Related Parties | $11.3K | $8.0K | ||||
| Research And Development Expense | $619.7K | $651.8K | ||||
| Operating Expenses | $1.8M | $2.7M | $300.0K | $427.8K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Stockholders Equity | -$713.6K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $6.2K | ||
| Retained Earnings Accumulated Deficit | -$3.0M | ||
| Prepaid Expense And Other Assets Current | $11.6K | ||
| Liabilities Current | $123.3K | ||
| Liabilities And Stockholders Equity | $422.1K | ||
| Liabilities | $390.2K | ||
| Common Stock Value | $79.0K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$407.0K | $404.3K | |
| Cash And Cash Equivalents At Carrying Value | $410.5K | ||
| Assets Current | $422.1K | ||
| Assets | $422.1K | ||
| Accounts Payable And Accrued Liabilities Current | $54.4K | ||
| Repayments Of Related Party Debt | $31.9K | ||
| Longterm Notes Payable Related Party | |||
| Advance Payable To Related Party | |||
| Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature | $398.2K | ||
| Accrued Interest Related Party | |||
| Property Plant And Equipment Net | |||
| Longterm Convertible Notes Payable Related Party | |||
| Stock Issued During Period Value Net Of Offering Costs And Warrant Liability | |||
| Convertible Long Term Notes Payable |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $8.2M | $9.7M | -$1.8M | -$1.4M | -$1.0M | -$714.0K | -$264.6K | $31.9K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $7.0M | $8.7M | $250.3K | $3.5K | $26.6K | $63.3K | $147.4K | $410.5K |
| Retained Earnings Accumulated Deficit | -$9.2M | -$7.5M | -$4.8M | -$4.4M | ||||
| Prepaid Expense And Other Assets Current | $2.1M | $1.6M | $9.6K | $9.6K | ||||
| Liabilities Current | $1.1M | $809.0K | $1.8M | $1.0M | ||||
| Liabilities And Stockholders Equity | $9.3M | $10.5M | $259.9K | $13.1K | ||||
| Liabilities | $1.1M | $809.0K | $2.0M | $1.4M | ||||
| Common Stock Value | $125.8K | $125.8K | $79.0K | $79.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $246.9K | -$263.1K | ||||||
| Cash And Cash Equivalents At Carrying Value | $7.0M | $8.7M | $250.3K | $3.5K | ||||
| Assets Current | $9.1M | $10.3M | $259.9K | $13.1K | ||||
| Assets | $9.3M | $10.5M | $259.9K | $13.1K | ||||
| Accounts Payable And Accrued Liabilities Current | $567.6K | $119.1K | $935.2K | $591.2K | ||||
| Repayments Of Related Party Debt | ||||||||
| Longterm Notes Payable Related Party | $500.0K | $500.0K | $250.0K | |||||
| Advance Payable To Related Party | $100.00 | $100.00 | $76.5K | |||||
| Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature | ||||||||
| Accrued Interest Related Party | $21.7K | $15.4K | $106.6K | |||||
| Property Plant And Equipment Net | $34.2K | $13.1K | ||||||
| Longterm Convertible Notes Payable Related Party | $346.8K | |||||||
| Stock Issued During Period Value Net Of Offering Costs And Warrant Liability | $1.6M | |||||||
| Convertible Long Term Notes Payable | $346.8K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 |
|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$733.5K | -$627.8K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$2.0K | $11.6K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $536.8K | $53.4K |
| Net Cash Provided By Used In Financing Activities | $326.5K | $1.0M |
| Proceeds From Repayments Of Related Party Debt | $76.5K | $9.0K |
| Proceeds From Notes Payable | $250.0K | |
| Share Based Compensation | $70.0K | |
| Proceeds From Issuance Of Common Stock | $1.1M | |
| Proceeds From Related Party Debt | ||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | ||
| Stock Issued During Period Value Share Based Compensation |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$20.3K | -$263.1K | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$40.00 | -$1.3K | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $344.0K | $5.2K | ||
| Net Cash Provided By Used In Financing Activities | $267.2K | |||
| Proceeds From Repayments Of Related Party Debt | ||||
| Proceeds From Notes Payable | $250.0K | |||
| Share Based Compensation | ||||
| Proceeds From Issuance Of Common Stock | ||||
| Proceeds From Related Party Debt | $17.2K | |||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $42.7K | $192.1K | ||
| Stock Issued During Period Value Share Based Compensation | $1.7M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 |
|---|---|---|
| Preferred Stock Shares Authorized | 10.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.01 | |
| Weighted Average Number Of Shares Outstanding Basic | 7.9M | 4.6M |
| Earnings Per Share Diluted | $-0.18 | $-0.17 |
| Earnings Per Share Basic | $-0.18 | $-0.17 |
| Common Stock Shares Outstanding | 7.9M | |
| Common Stock Shares Issued | 7.9M | |
| Common Stock Shares Authorized | 100.0M | |
| Common Stock Par Or Stated Value Per Share | $0.01 | |
| Weighted Average Number Of Diluted Shares Outstanding | ||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | |||
| Weighted Average Number Of Shares Outstanding Basic | 12.6M | 10.4M | 7.9M | 7.9M | 7.9M | 7.9M | ||
| Earnings Per Share Diluted | $-0.14 | $-0.26 | $-0.05 | $-0.04 | $-0.06 | $-0.04 | ||
| Earnings Per Share Basic | $-0.14 | $-0.26 | $-0.05 | $-0.04 | $-0.06 | $-0.04 | ||
| Common Stock Shares Outstanding | 12.6M | 12.6M | 7.9M | 7.9M | ||||
| Common Stock Shares Issued | 12.6M | 12.6M | 7.9M | 7.9M | ||||
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | ||||
| Common Stock Par Or Stated Value Per Share | $0.01 | $0.01 | $0.01 | $0.01 | ||||
| Weighted Average Number Of Diluted Shares Outstanding | 12.6M | 10.4M | 7.9M | 7.9M | 7.9M | 7.9M | ||
| Preferred Stock Shares Outstanding | ||||||||
| Preferred Stock Shares Issued |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 |
|---|---|---|
| Investment Income Interest | $2.8K | $7.8K |
| Additional Paid In Capital | $3.0M | |
| Accretion Expense | $80.0K | $5.1K |
| Stock Issued During Period Value New Issues | $1.1M | |
| Fair Value Adjustment Of Warrants | ||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $70.0K | |
| Adjustments To Additional Paid In Capital Warrant Issued | ||
| Stock Issued During Period Value Conversion Of Convertible Securities | ||
| Prepaid Expense Noncurrent | ||
| Warrants And Rights Outstanding |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|
| Investment Income Interest | $56.4K | $15.2K | $3.00 | $116.00 | $517.00 | $2.2K | |
| Additional Paid In Capital | $17.3M | $17.1M | $3.0M | $3.0M | |||
| Accretion Expense | $26.8K | $19.0K | |||||
| Stock Issued During Period Value New Issues | $11.6M | ||||||
| Fair Value Adjustment Of Warrants | -$12.9K | -$9.5K | |||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | |||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $161.6K | $139.4K | |||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $499.2K | ||||||
| Prepaid Expense Noncurrent | $129.7K | $184.0K | |||||
| Warrants And Rights Outstanding | $174.4K |
Most recent annual filing with the SEC: April 15, 2025
Data sourced from SEC EDGAR public filings as of August 8, 2026.